|
gptkbp:instanceOf
|
gptkb:drug
beta blocker
|
|
gptkbp:ATCCode
|
gptkb:C08CA01
|
|
gptkbp:bioavailability
|
60-65%
|
|
gptkbp:brand
|
gptkb:Norvasc
|
|
gptkbp:CASNumber
|
gptkb:88150-42-9
|
|
gptkbp:color
|
white
|
|
gptkbp:contraindication
|
unstable angina
cardiogenic shock
severe hypotension
|
|
gptkbp:developedBy
|
gptkb:Pfizer
|
|
gptkbp:discoveredBy
|
gptkb:Pfizer
|
|
gptkbp:eliminationHalfLife
|
30-50 hours
|
|
gptkbp:essentialMedicine
|
gptkb:WHO_Model_List_of_Essential_Medicines
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:firstApproval
|
1990
|
|
gptkbp:form
|
gptkb:tablet
oral suspension
|
|
gptkbp:genericAvailable
|
yes
|
|
gptkbp:hasMolecularFormula
|
C20H25ClN2O5
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
amlodipine
|
|
gptkbp:interactsWith
|
gptkb:milk
gptkb:simvastatin
CYP3A4 inhibitors
|
|
gptkbp:KEGGID
|
gptkb:D07451
|
|
gptkbp:lactation
|
unknown safety
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:maximumDose
|
10 mg/day
|
|
gptkbp:mechanismOfAction
|
inhibits calcium ion influx into vascular smooth muscle and cardiac muscle
|
|
gptkbp:MedlinePlusID
|
a692044
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:molecularWeight
|
408.88 g/mol
|
|
gptkbp:patentExpired
|
2007 (US)
|
|
gptkbp:pregnancyCategory
|
C
C (US)
|
|
gptkbp:proteinBinding
|
93-98%
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL573
gptkb:DB00381
2162
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
edema
dizziness
fatigue
palpitations
flushing
|
|
gptkbp:storage
|
20-25°C
|
|
gptkbp:UNII
|
216G2JHS5D
|
|
gptkbp:usedFor
|
hypertension
angina
|
|
gptkbp:usualAdultDose
|
5-10 mg once daily
|
|
gptkbp:bfsParent
|
gptkb:CYP3A4
gptkb:Exforge
|
|
gptkbp:bfsLayer
|
5
|